ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab ...

Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in ...

1. FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer ...

The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or ...

Overall, Lorusso characterizes the TroFuse-005 findings as convincing, citing the magnitude of benefit across key clinical ...

Tamim Niazi, MDCM, discusses key findings from the phase 3 DASL-HiCaP study presented at the 2026 ESMO Congress.

Rotow, MD, explains how RNA-based next-generation sequencing (NGS) fits into testing for newly diagnosed advanced nonsquamous non-small cell lung cancer (NSCLC) in a discussion moderated by Matthew A.

ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, ...

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as ...

Olomorasib is an investigational, selective KRAS G12C inhibitor with central nervous system activity. The phase 3 SUNRAY-01 ...

Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.

Hannah Naughton, MD, explains how de-escalating surgery and chemotherapy in breast cancer expands breast conservation and ...